After Another Covid Vaccine Delay, Novavax’s Opportunity Is Shrinking
Company Highlights Global Unmet Demand
Executive Summary
Novavax’s timelines are slipping once again, giving frontrunners Pfizer and Moderna the chance to consolidate their dominance in the market.